We discovered that cell death is often blocked in cancer cells, so we are actually attempting to develop medications that flip the organic cell death switch back on. Other studies on the cards for financing include the $15.7 million to the Australian National University task to explore autoimmune diseases, inflammation, immunodeficiency and allergy. Also planned is the $14.7 million University of Melbourne study on immunity, vaccine advancement in infectious disease or even cancer and diabetes. Then there may be the $12.6 million University of Melbourne study of how chemotherapy could possibly be used to boost the disease fighting capability and $8.7 million to the Nationwide Stoke Research Institute to develop new interventions to lessen the deaths and disability caused by stroke.The scholarly study is being led by Marc Mayberg, M.D.D., director of the Cerebrovascular Research Laboratory. The blood-brain barrier regulates the transportation of substances between circulating bloodstream and the brain. It is designed to allow entry in to the brain of important materials, such as nutrition, while keeping out harmful substances. Researchers, including those at The Cleveland Clinic, are already studying ways to artificially disrupt the blood-brain barrier to allow in substances that normally would be kept from reaching the brain, such as for example chemotherapy drugs for human brain cancer patients. This brand-new research project led by Drs. Mayberg and Janigro will look at ways to prevent barrier disruption instead of cause it.